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Insulin-Like Growth Factor-Binding Protein 7
Regulates Keratinocyte Proliferation, Differentiation
and Apoptosis
Janna Nousbeck1,2, Ofer Sarig2, Nili Avidan1, Margarita Indelman3, Reuven Bergman3, Michal Ramon3,
Claes D. Enk4 and Eli Sprecher1,2
Insulin-like growth factor (IGF)-binding protein 7 (IGFBP7) belongs to the IGFBP superfamily, which is involved
in the regulation of IGF and insulin signaling. Recently, a global gene expression study revealed that IGFBP7 is
downregulated in the psoriatic epidermis, with UVB phototherapy restoring its expression to normal. In the
present study, we confirmed that IGFBP7 expression is decreased in psoriatic lesions. Given the previous data
suggesting a role for IGFBP7 in the control of cancer cell growth, we investigated its involvement in the
regulation of keratinocyte (KC) proliferation and differentiation, which are abnormal in psoriasis. To model
IGFBP7 downregulation in vitro, we used IGFBP7-specific small interfering RNA or small hairpin RNA-expressing
lentiviral vectors in HaCaT cells or primary human KCs. Downregulation of IGFBP7 was found to markedly
enhance KC proliferation in both systems, was associated with a significant decrease in KC susceptibility to
tumor necrosis factor-a-induced apoptosis, but did not affect senescence. Downregulation of IGFBP7 was also
shown to block expression of genes associated with calcium-induced differentiation of human KCs. Finally,
recombinant IGFBP7 was found to inhibit KC proliferation and enhanced their apoptosis. These data position
IGFBP7 as a regulator of KC proliferation and differentiation, suggesting a potential role for this protein in the
pathophysiology and treatment of hyperproliferative dermatoses such as psoriasis.
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INTRODUCTION
Psoriasis is a chronic inflammatory skin disease affecting
B2% of the general population worldwide (Lowes et al.,
2007). The etiology of psoriasis is multifactorial and thought
to relate to interactions between environmental and genetic
factors. Typical histopathological features in psoriasis include
both epidermal (hyperparakeratosis) and immunological
(neutrophil microabscesses, dermal mononuclear infiltrate,
and blood vessel proliferation) abnormalities (Schon and
Boehncke, 2005; Griffiths and Barker, 2007; Lowes et al.,
2007). Accordingly, both immunological dysfunction and
epidermal defects are seemingly involved in the pathogenesis
of the disease, as exemplified by the nature of the candidate
genes found to be associated with genetic predisposition to
develop the disease (Nair et al., 2006, 2009; Zenz and
Wagner, 2006; Griffiths and Barker, 2007; Lowes et al., 2007;
Yang et al., 2008; Zenz et al., 2008; Zhang et al., 2009).
Recently, genomic-scale analysis of psoriatic skin revealed
marked upregulation of IGFBP7, encoding the insulin-like
growth factor (IGF)-binding protein 7 (IGFBP7), after photo-
therapy. IGFBP7 was found by immunohistochemistry to be
downregulated in psoriatic skin as compared with normal
skin, while UVB phototherapy was found to restore IGFBP7
expression in the epidermis to normal in parallel with
clearing of the lesions (Hochberg et al., 2007). These data
suggested that IGFBP7 upregulation may either be directly
affecting epidermal homeostasis or represent an epipheno-
menon of no direct relevance to psoriasis pathogenesis.
Insulin-like growth factor-binding protein 7 belongs to the
IGFBP superfamily, a large group of secreted proteins. A total
of 16 IGFBP family members have been identified, 6 of which
bind IGFs with a high affinity (IGFBP1–6), the other 10
members bind to IGFs with a low affinity (Burger et al., 2005).
IGFBP7 (also called IGFBP-rP1 or MAC25) binds IGFs with a
low affinity, but in contrast, recognizes insulin with a high
affinity, and thereby modifies its metabolism, distribution,
and ability to bind to the insulin receptor (Yamanaka et al.,
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1997). IGFBP7 has also IGF/insulin-independent actions.
For example, IGFBP7 contains a ‘‘follistatin module’’, which
enables it to bind to activin (Kato, 2000), a member of the
TGF-b (tumor growth factor b) superfamily of growth factors
(Tamura et al., 2007). IGFBP7 has been shown to regulate
cell proliferation, cell adhesion, cellular senescence, and
angiogenesis in different cancer cell lines, and it is therefore
considered to function as tumor suppressor gene in numerous
cancers (Akaogi et al., 1996; Wilson et al., 2002; Burger
et al., 2005; Ruan et al., 2007; Sato et al., 2007). More
recently, IGFBP7 has been shown to mediate senescence and
apoptosis in melanocytes, and to suppress melanoma growth
in vivo (Wajapeyee et al., 2008).
Insulin-like growth factor-binding protein 7 is expressed in
an ubiquitous fashion (Degeorges et al., 2000; Lopez-
Bermejo et al., 2003) and is inactivated by proteolytic
processing (Ahmed et al., 2003); in addition, hypermethyla-
tion has been reported to also affect its expression in
neoplastic tissues (Kanemitsu et al., 2000; Ahmed et al.,
2003; Lin et al., 2007). IGFBP7 expression is induced by
TGF-b (Burger et al., 2005), glucocorticoids (Pereira et al.,
1999), and retinoic acid (Swisshelm et al., 1995). IGFBP7 has
been found to be one of several keratinocyte (KC)-specific
genes differentially expressed in KCs compared with non-KC
cell types (Gazel et al., 2003).
Given the deranged expression of IGFBP7 in psoriasis and
its role in cancer cell growth, we studied its involvement in
the regulation of KC proliferation and differentiation, which
are typically abnormal in psoriasis. Our data suggest that
IGFBP7 may indeed regulate these processes in epidermal
cells, and as such may constitute an attractive target for
therapeutic interventions in common dermatoses.
RESULTS
IGFBP7 expression is decreased in psoriatic skin compared with
normal skin
Previous data showed that psoriasis is associated with
decreased expression of IGFBP7 (Hochberg et al., 2007). To
confirm these data in an independent set of patients, we
examined by immunohistochemistry the expression of
IGFBP7 protein in a series of psoriatic (n¼13) and control
(n¼13) biopsies (Figure 1). IGFBP7 was found to be
expressed strongly throughout the normal epidermis, whereas
its expression was either absent or very weak in psoriatic
epidermis (Figure 1). These and earlier data (Hochberg et al.,
2007) suggested that IGFBP7 may be involved in the
pathogenesis of psoriasis, a disorder characterized by
abnormal proliferation and differentiation of epidermal KCs.
IGFBP7 downregulation induces KC proliferation
As psoriasis has been shown to be associated with increased
cell proliferation and IGFBP7 has been shown to regulate cell
proliferation in cancer cells (Akaogi et al., 1996; Wilson
et al., 2002; Burger et al., 2005; Ruan et al., 2007; Sato et al.,
2007), we assessed the role for IGFBP7 expression in the
regulation of epidermal KC proliferation. We used small
interfering RNA (siRNA) and small hairpin RNA (shRNA) to
transiently and stably decrease IGFBP7 expression in HaCaT
cells, respectively, and used shRNA to transiently decrease
IGFBP7 expression in human primary KCs. Downregulation
of IGFBP7 was confirmed by quantitative reverse transcrip-
tase PCR (Figure 2a) and immunoblotting of the conditioned
media (Figure 2b). To exclude off-target effects of the siRNA
and shRNA used, we tested the effect of IGFBP7 down-
regulation on the levels of expression of other members of the
IGFBP family and found no significant changes in their
mRNA levels, suggesting that our siRNA and shRNA
specifically target IGFBP7 (Supplementary Figure 1S).
Downregulation of IGFBP7 in HaCaT cells increased cell
viability, as assessed by the MTT (3-(4, 5-dimethylthiazolyl-2)-2,
5-diphenyltetrazolium bromide) assay (Figure 3a), and cell
proliferation rates, as determined by BrDU incorporation
(Figure 3b). Concomitant with an increase in cell prolifera-
tion, the expression of KRT6, a marker of epidermal
proliferation, was upregulated in HaCaT cells (Figure 3c)
and primary KCs (Supplementary Figure 3S) downregulated
for IGFBP7. We confirmed these data in primary KCs using
both the MTT (Figure 3d) and the BrDU incorporation assays
(Figure 3e).
Decreased IGFBP7 expression is associated with decreased
apoptosis in KCs
Insulin-like growth factor-binding protein 7 has been shown
to induce cell apoptosis and senescence in a number of
cancer cell lines (Akaogi et al., 1996; Wilson et al., 2002;
Burger et al., 2005; Ruan et al., 2007; Sato et al., 2007;
Wajapeyee et al., 2008), two phenomena of potential
relevance to the pathogenesis of psoriasis (Wrone-Smith
et al., 1997). We assessed the effect of IGFBP7 down-
regulation on apoptotic activity in KCs. HaCaT cells were
stably or transiently transfected with either IGFBP7-specific
or control shRNA or siRNA, and apoptosis was estimated
using the TUNEL and annexin V assays. We found out that
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Figure 1. Insulin-like growth factor-binding protein 7 (IGFBP7) protein
expression in psoriasis. (a) Tissue sections obtained from patients affected
with plaque psoriasis (n¼ 13; lower panel) or from healthy controls (n¼ 13;
upper panel) were stained with mouse anti-IGFBP7 and counterstained with
hematoxylin. Bar¼ 40 mm. A control slide stained with non-immune serum is
shown in the middle panel; (b) Staining intensity was graded from 1–4 by two
independent observers. Data are presented as mean staining intensity grade.
Bars indicate the group means±SD (*Po0.01).
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decreased IGFBP7 expression in HaCaT cells lead to a
concomitant decrease in apoptotic activity, even in the
presence of 10 ngml1 of recombinant tumor necrosis factor
(TNF)-a (Figure 4a and b). Similarly, downregulation of
IGFBP7 by IGFBP7-specific siRNA in primary KCs prevented
TNF-a-induced cell apoptosis (Figure 4c).
In contrast, we did not observe any effect of IGFBP7
downregulation on senescence rates in human KCs (data not
shown).
IGFBP7 is required for calcium-induced expression of genes
associated with KC differentiation
To further investigate the role of IGFBP7 in epidermal
homeostasis, we induced differentiation of HaCaT cells
expressing either IGFBP7-specific or control shRNA in the
presence of 1.4mM Ca2þ medium, as previously described
(Boukamp et al., 1988). Downregulation of IGFBP7 was
found to block the induction of three markers of KC
differentiation, KRT10, involucrin (Figure 5a), and loricrin
(Supplementary Figure 4S). In parallel, cells downregulated
for IGFBP7 failed to show morphological changes, character-
istic of calcium-induced differentiation (Supplementary
Figure 2S). Similar results were obtained with primary KCs
(Figure 5b), suggesting that IGFBP7 may also be involved in
the regulation of KC differentiation. To further investigate this
possibility at a broader level, we performed a global gene
expression analysis to assess the effect of IGFBP7 down-
regulation on the expression of genes differentially expressed
in HaCaT cells cultured under low and high extracellular
calcium concentrations (Supplementary Table 2S). We found
that IGFBP7 downregulation significantly attenuated the
expression of 99.6 and 76.2% of genes displaying more than
2.5-fold change in expression in response to an increase in
extracellular calcium concentration in HaCaT cells and
primary KCs, respectively. A global pathway gene ontology
term analysis of the two data sets (P-value o0.01) show that
several of the process terms found to be significantly enriched
in the analysis were relevant to regulation of proliferation and
differentiation (Figure 5c). Taken together, these data suggest
that IGFBP7 regulates the expression of genes associated with
calcium-induced KC differentiation.
Recombinant IGFBP7 inhibits proliferation and induces
apoptosis in human KCs
To further confirm the involvement of IGFBP7 in the
regulation of KC proliferation and differentiation, we
examined the effect of recombinant IGFBP7 (rIGFBP7) on
primary KC cells. Addition of rIGFBP7 resulted in a decrease
in viable cell counts in primary human KC cultures, as
determined by the MTT assay (Figure 6a). This observation
was most probably accounted for by a decrease in cell
proliferation, as determined by the BrDU assay (Figure 6a), as
well as by an increase in KC apoptosis, as shown in Figure 6b.
rIGFBP7 lacked significant effect on cell differentiation (not
shown).
Effect of IGFBP7 downregulation on TGF-b and insulin signaling
To investigate the signaling pathway(s) affected by IGFBP7
downregulation, we used HaCaT cells stably downregulated
for IGFBP7. IGFBP7 downregulation was found to induce the
phosphorylation of insulin receptor-associated IRS-1 (insulin
receptor substrate 1) and of the tyrosine kinase, extracellular
signal-regulated kinase 1/2 (ERK 1/2), suggesting interference
with signaling through the insulin receptor (Figure 7). In
contrast, IGFBP7 did not influence SMAD 2/3 phosphoryla-
tion status (not shown).
DISCUSSION
Our results as well as that of a previous study (Hochberg
et al., 2007) indicate that the expression of IGFBP7 is
downregulated in the psoriatic epidermis. Although this mere
observation cannot imply in itself a direct causal role for
IGFBP7 in the pathogenesis of psoriasis, the fact that IGFBP7
has been shown to function as a tumor suppressor gene in
non-cutaneous systems (Swisshelm et al., 1995; Akaogi et al.,
1996; Wilson et al., 2002; Mutaguchi et al., 2003; Burger
et al., 2005; Ruan et al., 2007; Wajapeyee et al., 2008)
suggests that its low expression in psoriasis may contribute to
the pathogenesis of the disease. We therefore studied the
effect of IGFBP7 on four parameters of potential relevance to
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Figure 2. Downregulation of insulin-like growth factor-binding protein 7
(IGFBP7) expression in HaCaT cells and primary human keratinocytes (KCs).
(a) HaCaT cell lines and primary human KCs were either transfected with
small interfering RNA (siRNA) or infected with a lentiviral vector expressing
an IGFBP7-specific small hairpin RNA (shRNA). A non-specific siRNA or
shRNA served as controls. RNA was extracted after 48 hours of culture. mRNA
expression was normalized to ACTB or GAPDH (not shown). Results are
expressed as percent of control. Data shown represent mean values±SD of
three independent experiments performed in duplicates. (b) Protein extracts
from conditioned media obtained from HaCaT cells stably expressing an
IGFBP7-specific shRNA (shIGFBP7) or a non-specific shRNA (Co) were
analyzed by immunoblotting and probed using an anti-IGFBP7. Note
the significant decrease in IGFBP7 expression in the cells infected with
IGFBP7-specific shRNA.
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the disease cardinal features: cell proliferation, differentia-
tion, apoptosis, and senescence. We found that low IGFBP7
expression triggered cell proliferation, blocked differentia-
tion, decreased apoptosis, and had no effect on senescence
rates both in HaCaT cells and in primary human KCs.
Conversely, rIGFBP7 was found to induce cell apoptosis and
to decrease cell proliferation.
These data may bear direct relevance to the pathogenesis
of psoriasis. Indeed, excessive KC proliferation is character-
istic of psoriasis (Krueger and Bowcock, 2005; Lowes et al.,
2007); in addition, psoriatic KCs display a number of markers
of proliferation, such as KRT6a (McKay and Leigh, 1995),
which was also found to be induced by IGFBP7 down-
regulation in cultured KCs. Conversely, KC differentiation is
altered in the psoriatic epidermis (McKay and Leigh, 1995;
Krueger and Bowcock, 2005; Lowes et al., 2007), and in KCs
expressing decreased IGFBP7 levels, calcium-induced differ-
entiation was similarly blocked. More specifically, IGFBP7
downregulation was associated with attenuation of calcium-
induced KRT10 upregulation; similarly, KRT10 expression is
low in psoriasis (Bernerd et al., 1992; Bovenschen et al.,
2005), whereas various treatment modalities restores KRT10
expression to normal in the psoriatic epidermis (Vissers et al.,
2008). Of note, despite the fact IGFBP7 downregulation
brought about a decrease in involucrin upregulation during
differentiation, involucrin expression has been shown to be
upregulated in psoriasis (Haider et al., 2006). IGFBP7 was
also found to regulate apoptotic activity in cultured KCs:
IGFBP7 downregulation almost completely abrogated
TNF-a-induced KC apoptosis, whereas rIGFBP7 significantly
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Figure 3. Antiproliferative effect of insulin-like growth factor-binding protein 7 (IGFBP7) on keratinocytes (KCs). (a) Cell viability was assessed using the MTT
(3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay in HaCaT cells downregulated for IGFBP7 using small interfering RNA (siRNA) and
cultured for 24 and 72 hours, as well as in HaCaT Cells stably expressing an IGFBP7-specific small hairpin RNA (shRNA) or a control shRNA (Co). Data represent
mean values±SD of three independent experiments. *Po0.01 compared with control cells. (b) HaCaT Cells stably expressing an IGFBP7-specific shRNA or a
control shRNA (Co) were assessed using the BrDu assay (stable transfection). Data represent mean values±SD of three independent experiments. *Po0.01
compared with control cells. (c) KRT6a mRNA and protein levels were assessed by quantitative reverse transcriptase PCR (left panel) and immunoblotting (right
panel) in HaCaT cells stably expressing an IGFBP7-specific shRNA or a control shRNA (Co). Primary KCs were transiently transfected with IGFBP7-specific
siRNA (IGFBP7) or with control siRNA (Co) and assessed using (d) the MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide) assay (24 and 48-
hours posttransfection) and (e) the BrDu assay (24 hours posttransfection). Data represent mean values±SD of three independent experiments (*Po0.01
compared with control cells).
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augmented the apoptotic response of the cells. Conflicting
data on the role of apoptosis in the pathogenesis of psoriasis
(Bowen et al., 2004; Gunduz et al., 2006; Yang et al., 2009)
may reflect the fact that apoptotic activity significantly
changes depending on the stage of evolution of the psoriatic
plaque, with markedly decreased apoptotic indices being
found in the established lesions and increased apoptosis
correlating with regression (Laporte et al., 2000). In fact, most
studies lend support to a role for decreased apoptosis in the
pathogenesis of psoriasis (Raj et al., 2006). Of note, serum
stimulation was found to downregulate IGFBP7 expression,
suggesting a possible role for growth factor (for example,
EGFR) signaling in the regulation of IGFBP7 expression
(Supplementary Figure 5S). In contrast we did not observe
any effect of calcium on IGFBP7 expression (not shown).
Insulin-like growth factor-binding protein 7 has been
shown to bind and block the activity of activins, members of
the TGF-b superfamily of growth factors (Kato, 2000).
Activins are thought to have a complex role in skin
homeostasis, promoting KC differentiation (Seishima et al.,
1996) or epidermal thickening (Munz et al., 1999), and
stimulating fibroblast proliferation (Mukhopadhyay et al.,
2007), especially in the context of wound healing, a process
considered by many to be in some aspects reminiscent of
psoriasis (Nickoloff et al., 2006). We did not detect a
significant effect of IGFBP7 downregulation on SMAD
phosphorylation (not shown). IGFBP7 has also been shown
to bind, and thereby modulate, the activity of IGFs and
insulin. Interestingly, insulin and IGF-1 signaling pathways
have been shown to enhance KC proliferation (Neely et al.,
1991; Wertheimer et al., 2001; Sadagurski et al., 2007) and to
be involved in skin differentiation (Wertheimer et al., 2000,
2001; Sadagurski et al., 2007). The fact that IGFBP7 is able to
block insulin (and to a lesser degree IGF-1) binding to its
receptors (Yamanaka et al., 1997) suggests a possible
pathway through which IGFBP7 may affect KC differentiation
and growth. Accordingly, IGFBP7 downregulation was found
to be associated with increased levels of phosphorylated
IRS-1 and ERK 1/2, which attests to the activation of the
insulin signaling pathway (Genua et al., 2009). Interestingly,
increased levels of phosphorylated ERK 1/2 were also
observed in lesional psoriatic skin (Yu et al., 2007).
In conclusion, independent of their possible relevance to
the pathogenesis of psoriasis (which initially motivated this
study), our data position IGFBP7 as a key regulator of KC
differentiation and proliferation, and therefore suggest that
this protein may represent an attractive target for the
treatment of dermatoses associated with KC abnormal
proliferation and differentiation.
MATERIALS AND METHODS
Cell cultures
HaCaT cells, a spontaneously immortalized human KC line, were
kindly provided by Dr Dina Ron (Technion, Haifa, Israel). The cells
were maintained in high-glucose DMEM medium containing 0.075
or 1.4mM CaCl2 supplemented with 10% fetal calf serum, 1%
L-glutamine, and 1% penicillin/streptomycin (Biological Industries,
Beit-Haemek, Israel).
Primary human KCs were purchased from CELLnTEC Advanced
Cell Systems (Bern, Switzerland). Cells were grown in KC growth
medium containing 0.15mM CaCl2 supplemented with growth factor
bullet kit (Lonza, Walkersville, MD). Medium was changed every
2–3 days. Cells were used at passage 3. For differentiation, cells were
cultured in KC growth media and 1.4mM CaCl2.
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Figure 4. Decreased insulin-like growth factor-binding protein 7 (IGFBP7)
expression is associated with decreased apoptosis in human keratinocytes.
(a) HaCaT cells stably expressing IGFBP7-specific (IGFBP7) or control
small hairpin RNA (shRNA) (Co), were exposed to 10 ng ml1 of recombinant
TNF-a (þ ) or vehicle () 24 hours after transfection. Apoptosis was measured
using the TUNEL assay. (b) HaCaT cells stably expressing IGFBP7-specific
(IGFBP7) or control shRNA (Co), were exposed to 10 ng ml1 of recombinant
TNF-a (þ ) or vehicle () 24 hours after transfection. Apoptosis was measured
using the Annexin V assay. (c) Primary KCs were transiently transfected with
IGFBP7-specific small interfering RNA (siRNA) (IGFBP7) or with scrambled
control siRNA (Co) and exposed to 10 ng ml1 of recombinant TNF-a (þ )
or vehicle (). Apoptotic activity was assessed by the TUNEL assay. All
experiments were repeated thrice. Results are provided as mean values±SD.
Results were considered significant for *Po0.01.
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Immunohistochemistry
Formaldehyde-fixed 5-mm paraffin-embedded sections were treated
with 3% H2O2 in methanol for 15minutes at room temperature,
warmed in a microwave oven in citrate buffer for 15minutes at 90 1C,
and stained with mouse monoclonal anti-IGFBP7 antibodies (Abs) (R&D
Systems, Minneapolis, MN), anti-keratin 14 Abs (BioGenex, San Ramon,
CA), or preimmune rabbit antiserum for 1hour at room temperature.
After extensive washings in phosphate-buffered saline (PBS), the Abs
were revealed using the ABC technique (Zymed Laboratories, South San
Francisco, CA) and the slides were counterstained with hematoxylin.
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Figure 5. Insulin-like growth factor-binding protein 7 (IGFBP7) is required for calcium-induced keratinocyte (KC) differentiation. (a) HaCaT cells stably
expressing an IGFBP7-specific or a control small hairpin RNA (shRNA) were induced to differentiate by increasing the extracellular calcium concentration.
KRT10 and involucrin (INV) gene expression was assessed as a measure of differentiation-associated events. Data represent mean values±SD of three
independent experiments performed in duplicate. (b) Primary human KCs stably expressing an IGFBP7-specific or a control shRNA were induced to differentiate
by increasing the extracellular calcium concentration. KRT10 and involucrin (INV) gene expression was assessed as a measure of early and late differentiation-
associated events, respectively. Data represent mean values±SD of three independent experiments performed in duplicate; (c) A global process gene ontology
(GO) term analysis was performed using the top 100 genes that showed a maximal response (in data sets obtained in primary KCs and in HaCaT cells) to IGFBP7
silencing, after calcium induction. Significant terms (P-valueo0.01) encompass processes of direct relevance to cell proliferation and differentiation. The green
bars correspond to the observed frequency of the GO terms identified as compared with their expected frequency (brown bars).
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Figure 6. Recombinant insulin-like growth factor-binding protein 7 (IGFBP7) inhibits keratinocyte (KC) proliferation and induces apoptosis in KCs. Primary
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siRNA transfection
Primary KC cells were cultured in six-well plates at a density of
8 104 cells per well before transfection with 66 nmol l1 siRNA
duplexes against IGFBP7 or negative control siRNA (Invitrogen,
Carlsbad, CA) using Lipofectamine 2000 (Invitrogen). We tested five
different siRNA species for downregulation of IGFBP7. The siRNA
IGFBP7 duplex that we selected for further use in this study
consisted of 50-rGrCUrGrGUrAUrCUrCrCUrCUrArArGUTT-30 and
50-rArCUUrArGrArGrGrArGrAUrArCrCrArGrCTT-30 (Sigma-Proligo,
The Woodlands, TX). As a negative control, we used a standard
scrambled siRNA purchased from Invitrogen.
shRNA lentiviral transduction
To achieve stable gene downregulation, we used a DNA shRNA-
expressing lentiviral vector containing viral packaging signals,
regulatory elements, and puromycin resistance gene to package the
shRNA sequence into infectious virions (Sigma-Aldrich, St Louis, MO).
We transduced HaCaT cells with shRNA lentiviral particles
according to the manufacturer’s recommendations. Briefly, 24 hours
before transduction, cells were grown in six-well plates up to
1.6 104 cells per well. 1–5ml of viral stock and 2ml of 4mgml1
polybrene were added to the cells and incubated for 18–20 hours at
37 1C in 5% CO2-humidified incubator. The amount of the viral
stock was determined according to desired MOI (multiplicity of
infection) (MOI¼ 5) and total transducing units (TU) per milliliter,
supplied by Sigma. The formula for calculation is (total number of
cells per well) (desired MOI)¼ total TU needed; TU needed/(TU
per ml supplied)¼ total milliliter of lentiviral particles for each well.
At 24 hours after transduction, the cells were washed twice in
1 PBS and maintained in complete growth medium. After
expansion in culture for 48 hours, the cells were maintained in
growth medium supplemented with puromycin at a final concentra-
tion of 4mgml1. Selection was performed in the presence of
puromycin for 1 week. Selected clones were frozen in liquid
nitrogen before further use.
Primary KCs were transduced according to the same protocol as
described for HaCaT cells with slight modifications. At 24 hours after
transduction, the cells were washed twice in 1 PBS and
maintained in KC growth medium containing 0.15mM or 1.4mM
CaCl2. After expansion in culture for 72 hours, the cells were used for
in vitro assays.
Quantitative reverse transcription PCR
RNA was extracted from the cultured cells using an RNA extraction
kit (Roche, Mannheim, Germany). cDNA was synthesized from
500ng of total RNA using the Reverse-iT first strand synthesis kit
(ABgene, Epson, UK) and random hexamers. cDNA PCR amplifica-
tion was carried out using the SYBR Green JumpStart Taq ReadyMix
(Sigma-Aldrich) on a Mx3000p/5p multifilter system (Stratagene,
Cedar Creek, TX) with gene-specific intron-crossing oligonucleotide
pairs listed in Supplementary Table S1. To ensure the specificity of
the reaction conditions, at the end of the individual runs, the melting
temperature (Tm) of the amplified products was measured to confirm
its homogeneity. Cycling conditions were as follows: 95 1C for
10minutes, 95 1C for 10 seconds, 62 1C for 15 seconds, and 72 1C for
25 seconds for a total of 40 cycles. Each sample was analyzed in
triplicate. For quantification, standard curves were obtained using
serially diluted cDNA amplified in the same real-time PCR run.
Results were normalized to ACTB and GAPDH mRNA levels. After
the quantification procedure, the products were resolved by 2.5%
agarose gel electrophoresis to confirm that the reaction had
amplified DNA fragments of expected size.
Microarray hybridization and data analysis
Total RNA (200 ng) was reverse transcribed and cRNA prepared
using TotalPrep RNA Amplification Kit (Applied Biosystems/Ambion,
Austin, TX) according to the manufacturer’s protocol. 1.5 mg of
biotinylated cRNA was hybridized to Sentrix Human WG-6 v2 array
(encompassing 48,701 transcript targets), washed, and scanned on a
BeadArray Reader (Illumina, San Diego, CA). The scanning data
were exported to MatLab sofware (MathWorks, Natick, MA),
quantile normalized, and transcripts with detection P-value 40.01
were removed from the analysis (more than 13,000 transcripts had a
P-valueo0.01). In the global gene ontology term analysis, we tested
all gene ontology terms that were present in our gene set more than
once. The gene set was composed of the top 100 genes whose
calcium-induced up- or downregulation was most markedly affected
by IGFBP7 silencing. For each term, we randomly selected the same
number of genes as in our gene set and calculated the number of
times it appeared in this set. We repeated the process 100 times and
built a histogram of this gene ontology term frequency. The results
were analyzed using the one-sample Wilcoxon signed-ranks test to
assess relative enrichment in our experimental gene set.
Western blotting
Cells were homogenized in Cellytic MT lysis/extraction reagent
(Sigma-Aldrich) and protease inhibitors mix, including 1mM
phenylmethanesulphonylfluoride, and 1mgml1 aprotinin and
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Figure 7. Effect of insulin-like growth factor-binding protein 7 (IGFBP7)
down regulation on signaling through the insulin receptor. To assess the
effect of IGFBP7 downregulation on signaling through the insulin receptor,
protein was extracted from HaCaT cells stably expressing an IGFBP7-specific
small hairpin RNA (shRNA) or a control shRNA. Protein extracts were
analyzed using immunoblotting with antibodies directed against
phosphorylated IRS-1 (p-IRS), IRS-1, phosphorylated ERK 1/2 (p-ERK), ERK2,
and b-actin. Band intensity was assessed by densitometry. The experiments
were repeated thrice and a graph depicting the mean±SD is given below
each corresponding gel. *Po0.01
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leupeptin (Sigma-Aldrich). Following centrifugation at 10,000 g for
10minutes at 4 1C, proteins were electrophoresed through a
10% SDS-PAGE and transferred onto a nitrocellulose membrane
(Trans-Blot, Bio-Rad, Hercules, CA). After blocking for 1 hour using
1 Tris-buffered saline (20mM Tris, 150mM NaCl) with 3% BSA and
0.01% Tween 20, blots were incubated with primary Abs. The
primary Abs included Abs to p-IRS-1, IRS-1, p-ERK 1/2, ERK 2,
SMAD 2/3, p-SMAD 2/3 (Santa Cruz Biotechnology, Santa Cruz,
CA); IGFBP7 (R&D Systems), and cytokeratin 6 (Abcam, Cambridge,
MA). The blots were washed thrice with Tris-buffered saline–Tween 20
(20mM Tris HCl, 4mM Tris base, 140mM NaCl, 1mM EDTA, and 0.1%
Tween 20). After incubation with secondary horseradish peroxidase-
conjugated anti-mouse or anti-rabbit Ab (Sigma-Aldrich), and sub-
sequent washings, proteins were detected using the EZ-ECL chemilu-
minescence detection kit (Biological Industries). To compare the
amount of protein in different samples, the blots were re-probed using
a mouse mAb to b-actin (Abcam, Cambridge, UK) and secondary
horseradish peroxidase-conjugated anti-mouse Ab (Sigma-Aldrich).
MTT assay
The MTT test is based on the selective ability of living cells to reduce
the yellow salt MTT (Sigma-Aldrich) to a purple-blue insoluble
formazan precipitate. MTT was dissolved in PBS at 5mgml1 and
added to each well (10% of total volume) for 30-minute incubation
at 37 1C. After incubation, the media was removed and the purple
formazan product dissolved in DMSO. The supernatants were
collected and then scanned with an ELISA reader Zenyth 200
(Anthos Labtec, Cambridge, UK) at 560 nm.
BrDu assay
The incorporation rate of BrdU was determined by Cell Proliferation
ELISA BrdU colorimetric kit (Roche) according to the manufacturer’s
protocol. Absorbance at 450nm was measured using an ELISA reader.
Briefly, cells were cultured in six-well plates and incubated with BrdU
for 6hours at 37 1C. Then the cells were fixed and the DNA was
denatured by adding FixDenat solution (Roche Applied Science,
Penzberg, Germany). The anti-BrdU peroxidase conjugated Ab was
added for 90minutes at room temperature and the cells were rinsed.
Immune complexes were detected by adding substrate solution at an
absorbance of 450nm using ELISA reader Zenyth 200 (Anthos Labtec).
TUNEL assay
Apoptosis was assessed using the TUNEL kit (Roche) according to
the manufacturer’s protocol. Briefly, cells were plated on cover slips
with or without the addition of 10 ngml1 of TNF-a (PeproTech,
Rocky Hill, NJ) for 12 hours, air-dried, and fixed with a freshly
prepared fixation solution (4% paraformaldehyde in PBS) and then
rinsed twice with PBS. Cells were permeabilized with 0.1% Triton
X-100 in 0.1% sodium citrate solution. Cell samples were incubated
in a humidified atmosphere for 1 hour at 37 1C in the dark and in the
presence of the TUNEL reaction mixture, and counterstained with
DAPI (4’,6-diamidino-2-phenylindole). More than 1,000 cells were
counted for each slide and examined under a fluorescent micro-
scope Zeiss Axioscope 2 (Carl Zeiss MicroImaging, Thornwood, NY).
Image analysis was performed with Image-Pro Plus 5 software
(Media Cybernetics, Bethesda, MD). Differences in apoptotic activity
were considered significant at P-values o0.01 calculated using a
standard student’s t-test.
Annexin V assay
Annexin V assay was performed using ApoAlert Annexin V
Apoptosis Kit (Clontech Laboratories, Mountain View, CA) according
to the manufacturer’s protocol. Briefly, cells were plated on cover
slips with or without the addition of 10 ngml1 of TNF-a
(PeproTech) for 12 hours, rinsed with the supplied binding buffer
and incubated with Annexin V and propidium iodide at room
temperature for 15minutes in the dark. Hoechst stain was used to
counterstain the cells. More than 1,000 cells were counted for each
slide and examined under a fluorescent microscope (Carl Zeiss
MicroImaging). Image analysis was performed with Image-Pro Plus 5
software. Differences in apoptotic activity were considered significant
at P-values o0.01 calculated using a standard student’s t-test.
Senescence-associated b-galactosidase assay
Cells were seeded 48hours before staining at a concentration of 2 to
4 104 cells per well in six-well plates. This cell density ensures
that the staining is performed before the cultures reach confluency.
SA-b-Gal (senescence-associated b-Gal) staining was performed, as
previously described, with minor modifications (Dimri et al., 1995).
Briefly, the cells were washed with cold PBS and fixed for 5minutes
with 0.5% glutaraldehyde diluted in cold PBS. After fixation, cells were
washed in PBS and incubated for 8 hours at 37 1C in staining solution
containing 1mgml1 5-bromo-4-chloro-3-indolyl-b-D-galactoside
(X-Gal) (Roche) and the rest of the components as previously described
(Dimri et al., 1995). For staining at different pH values, 0.1M citric acid
and 0.2M Na2HPO4 solutions were mixed at appropriate proportions.
After the incubation period at 37 1C, cells were washed thrice with
cold PBS and stored in PBS at 4 1C until images were collected.
Quantitative analysis of the images was performed using a Matlab
application for cell marking (SegmentGui) and color analysis
(http://md.technion.ac.il/pictures/storage/45/47.zip). For each mea-
surement, a minimum of 250 randomly chosen cells were marked
manually. Kolmogorov–Smirnov test was used for statistical analysis.
Differences below P-value of 0.05 were considered significant.
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